This is an early access version
,
Department of oncology, West Kazakhstan Marat Ospanov State Medical University , Aktobe , Kazakhstan
,
Department of Radiology, West Kazakhstan Marat Ospanov State Medical University , Aktobe , Kazakhstan
,
Department of Oncology, West Kazakhstan Marat Ospanov State Medical University , Aktobe , Kazakhstan
,
Medical Centre, 4. Department of Pathomorphology, West Kazakhstan Marat Ospanov State Medical University , Aktobe , Kazakhstan
,
Department of Radiology, West Kazakhstan Marat Ospanov State Medical University , Aktobe , Kazakhstan
,
Department of Oncology, West Kazakhstan Marat Ospanov State Medical University , Aktobe , Kazakhstan
,
Department of Oncology, West Kazakhstan Marat Ospanov State Medical University , Aktobe , Kazakhstan
,
Medical Centre, 8. Department of Pathomorphology, West Kazakhstan Marat Ospanov State Medical University , Aktobe , Kazakhstan
,
Department of Oncology, West Kazakhstan Marat Ospanov State Medical University , Aktobe , Kazakhstan
,
Department of Oncology, West Kazakhstan Marat Ospanov State Medical University , Aktobe , Kazakhstan
,
Department of Oncology, West Kazakhstan Marat Ospanov State Medical University , Aktobe , Kazakhstan
Department of Oncology, West Kazakhstan Marat Ospanov State Medical University , Aktobe , Kazakhstan
Aim. Colorectal cancer (CRC) ranks among the leading causes of cancer-related mortality worldwide, with significant incidence and mortality rates recorded in Kazakhstan. CRC poses a substantial healthcare burden, prompting investigations into novel prognostic markers.
Aim. This study investigates the prognostic significance of CD163 expression in patients with colorectal cancer.
Methods. This retrospective cohort study was conducted in Aktobe, Kazakhstan, utilizing tissue microarrays from 175 patients diagnosed with Tumor, Node, Metastasis (TNM) stage I–IV colon adenocarcinoma. CD163 expression was assessed through immunohistochemistry. Kaplan-Meier survival analysis was employed to estimate 5-year overall survival, defined as the interval from diagnosis to death or last follow-up. Cox proportional hazards models were used to evaluate the relationship between CD163 expression levels and survival outcomes.
Results. High CD163 expression was linked to advanced disease stage of colorectal cancer (p < 0.001), lymphovascular invasion (p < 0.001), perineural invasion (p < 0.001), and Collagen I>30%, A type (p<0.001). CD163 infiltration was a negative prognostic factor for colorectal cancer patients, with higher risks of death in the high CD163 expression group compared to the low CD163 group (HR=5.769, 95% CI 3.194 – 10.42, p<0.001).
Conclusion. The findings highlight CD163 as a potential prognostic biomarker in CRC, warranting further investigation into its mechanistic role and therapeutic implications.
Conceptualization, N.I., Y.I. and A.K.; Data curation, N.I., Y.I. and A.Z.; Formal Analysis, N.I. and Y.I.; Methodology, N.I. and A.Z.; Project administration, N.I., B.B., N.K. and Z.S.; Resources, N.I., A.I., A.T. and D.Z.; Software, N.I., Y.I., A.K. and A.Z.; Supervision, N.I., Y.I., A.K., A.Z. and Z.S.; Validation, N.I., Y.I., M.A. and A.Z.; Writing – original draft, N.I., M.A. and A.Z.; Writing – review & editing, Y.I., A.K., A.Z., B.B., N.K., Z.S., A.I., A.T. and A.Z.; Investigation, N.K., Z.S., A.I. and A.T.; Visualization, A.T. and D.Z. All authors have read and agreed to the published version of the manuscript.
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
The authors declare that no financial support was received for the research, authorship, and/or publication of this article.
Authors retain copyright. This work is licensed under a Creative Commons Attribution 4.0 International License. 
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.